



**RE: VALDECOXIB (Bextra®/Valdyn®) and PARECOXIB SODIUM (Dynastat®/Rayzon®) and cardiovascular safety**

Following the release of the Committee for Human Medicinal Products' (CHMP) statement on the contraindication of valdecoxib and parecoxib in patients following coronary artery bypass graft (CABG) surgery. The Medicines Authority (MA) would like to inform prescribers to follow carefully the latest recommendations which the CHMP has made in the **press release** and Summary of Product Characteristics issued by the European Medicines Agency.